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1  an introDuction to array comParative genomic   
 hyBriDisation (acgh)
Array comparative genomic hybridisation (aCGH) represents a major advance in 
the field of cytogenetics and offers tremendous promise in prenatal diagnosis for 
detecting genetic alterations leading to serious genetic conditions. The technology, 
also sometimes known as molecular karyotyping, can detect differences in DNA 
copy number at hundreds or thousands of points in the genome simultaneously. 
This technology promises to replace standard karyotyping, which uses standard 
microscopy to view chromosomes directly in order to detect structural variations that 
lead to conditions such as Down syndrome (which can be caused by trisomy 21, that 
is three copies of chromosome 21 instead of two, or a joining of chromosomes 21 and 
14) or Turner syndrome (loss of one copy or part of one copy of the X chromosome 
in girls), or genetic duplications, deletions, insertions or translocations (some of 
which can be associated with hereditary diseases or cancers). Compared to standard 
karyotyping, aCGH can detect genetic variations at a much higher resolution. 
aCGH was initially studied and utilised in cancer genetics to determine how 
chromosome structure and function contributed to tumour development.1 Although 
it is still used for this purpose, it is hoped that aCGH will be valuable in other 
clinical contexts, including prenatal screening and diagnosis. In research, aCGH has 
demonstrated an unparalleled ability to perform comprehensive, high-resolution 
scans of both the whole genome and specific chromosomal regions. Physicians 
are looking to aCGH to increase their ability to detect clinically significant genetic 
alterations. Although it is already a powerful research tool, the technology is still in 
its early stages and has not fully transitioned to clinical use. However, in the United 
States, aCGH is already being offered as a clinical test in postnatal and prenatal 
settings. More research is necessary to determine how and in what capacity aCGH 
technology can and should be used for clinical prenatal screening or diagnosis. A 
necessary aspect of this development is a thorough consideration of the ethical 
implications of the new technology; this will come to the forefront as clinical use of 
aCGH increases. 
2  Prenatal Diagnostic techniQues anD acgh
In the last four decades, techniques designed to detect chromosomal abnormalities 
in prenatal diagnosis have developed significantly from the early use of chromosome 
banding techniques to the more advanced technologies available today. Because 
chromosome analysis plays an integral role in the detection and diagnosis of many 
genetic disorders, technology that allows clinicians to identify cytogenetic imbalances 
with increased precision and speed is a high research priority. Banding techniques, 
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which have been used in prenatal diagnosis since the 1970s, can detect aneuploidy 
(an abnormal number of chromosomes), and large structural rearrangements of 
chromosomes such as deletions, duplications and translocations, by evaluating 
metaphase cells.2,3,4 This type of chromosome analysis reliably detects deletions and 
duplications >10Mb, but smaller structural rearrangements will not be detected 
without higher resolution capability.5 Banding techniques are able to detect 
alterations as small as 3–5Mb, but this higher-resolution technology is not routinely 
applied because it is labour-intensive and therefore costly.2,3,4 Other limitations 
regarding the use of these methods include the need for cultured cells (metaphase 
cells), requiring additional time, and the difficultly of interpreting data.3,4 To address 
these limitations, as well as the need for higher resolution methods that would permit 
reliable detection of chromosomal abnormalities smaller than 3Mb, researchers have 
developed and used alternative techniques, such as fluorescence in situ hybridisation 
(FISH) and quantitative fluorescent polymerase chain reaction (QF-PCR).2,3
When used for prenatal diagnosis, both FISH and QF-PCR methods are useful tools 
in detecting chromosome alterations. The process of FISH involves hybridising 
fluorescently labelled DNA probes to targeted regions on human chromosomes 
enabling researchers to screen for aneuploidy and to detect submicroscopic 
abnormalities in those specific locations.4 Of particular interest for prenatal 
diagnosis are the common aneuploidies of chromosomes 13 (Patau syndrome), 
18 (Edward syndrome), 21 (Down syndrome), X and Y, which account for the vast 
majority of chromosome abnormalities affecting the human population.2, 4 The 
advantages of this technique include increased resolution (size of individual probes 
(~35–200kb)) and rapid detection of alterations by locus-specific probes.4,6 QF-
PCR is another technique employed in prenatal diagnosis. It works by using primer 
pairs that quantitatively amplify polymorphic, chromosome-specific sequences in 
order to detect genomic alterations.4 Similar to FISH, QF-PCR is used for the more 
common aneuploidies mentioned above, and for sex-chromosome aneuploidy.4 
It is a relatively quick and efficient alternative to more labour-intensive processes 
because it does not require cultured cells and is amenable to automation.3,4 There 
are, however, a number of limitations to both FISH and QF-PCR procedures. The 
primary challenge is that neither of these two methods provides a comprehensive, 
whole-genome screen, resulting in a failure to detect approximately 1–2 per cent of 
abnormalities in prenatal diagnosis.4 Because both techniques require targeted probes, 
some alterations detected by conventional karyotype analysis will not be detected.3,4,7 
Furthermore, the successful use of FISH and QF-PCR probes requires suspicion 
regarding a particular region so that specific probes can be utilised. The limitations 
of these prenatal diagnostic techniques prompted researchers to continue developing 
methods that would enable them to perform a high-resolution, comprehensive screen 
of the human genome in order to detect more chromosome abnormalities. 
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The introduction of aCGH, a technique similar to conventional comparative genomic 
hybridisation (CGH), has demonstrated considerable potential in its ability to detect 
copy number variation in DNA at significantly increased resolution.3,6 The first step 
of this relatively new process involves taking two genomic DNA samples – a patient 
(test) sample, and a reference (control) sample – then differentially labelling them with 
fluorescent dyes (cyanine-3 and cyanine-5, for example).3 The two genome samples 
are then mixed together and hybridised to a genomic microarray, consisting of DNA 
fragments fixed on the surface of a slide. These DNA fragments or targets can exist in a 
variety of forms, including (the most commonly used) bacterial artificial chromosomes 
(BACs); PCR-generated sequences; cDNA clones; and oligonucleotides.2,7 When 
hybridised, the two genomic samples compete for binding to the targets on the slide, thus 
creating a profile of relative dye intensities that can be read by a laser scanner.8 Deletions 
and duplications are detected by differing signal intensities of the respective dyes. To 
increase reliability, the process can be repeated a second time by reversing the dyes and 
analysing the scanned product, thereby confirming the initial result.8 This procedure is 
illustrated in Figure 1 with the initial and duplicate processes represented. 
Figure 1: The aCGH process
DNA from a patient sample and a control sample are labelled with a different fluorophore, 
Cy3 (green) versus Cy5 (red), mixed and hybridised to an array of cloned genomic DNA 
fragments (shown as black spots). Two different hybridisations with dye reversal are performed 
(compare left to right panels). The hybridised slides are scanned with a laser scanner and the 
signal intensities of all fragments for each of the fluorophores (shown as coloured spots) are 
analysed using specialised software. A gain (duplication) in the patient of DNA fragment(s) 
present on the slide will give a more intense signal compared to the control; a loss (deletion) 
in the patient will produce a less intense signal compared to the control. 
Source: Van den Veyver I.B., Beaudet A.L. Comparative genomic hybridization and 
prenatal diagnosis. Curr Opin Obstet Gynecol 2006 18: 185–91
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Different arrays have been constructed for different purposes, and researchers have 
developed arrays to analyse specific chromosomes and segments of chromosomes, 
referred to as targeted arrays, as well as arrays that cover the entire human genome, 
referred to as whole-genome arrays.2,7 Targeted arrays are site specific, enabling 
researchers to examine a precise chromosomal region of particular interest. 
Genome-wide screens, in contrast, provide a comprehensive analysis of the whole 
genome. This ability to perform an extremely high-resolution screen of the entire 
genome sets aCGH technology apart from other prenatal diagnostic techniques, and 
is of tremendous value to researchers. In the research context, it can be used for 
the discovery of genes or the detection of copy gains and losses.7 It is not yet clear 
what role an aCGH whole-genome screen will play in the use of aCGH for prenatal 
diagnosis due to limitations that will be discussed later. 
As aCGH technology continues to develop, even higher-resolution microarrays are 
now constructed using a ‘tiling’ approach in which researchers can arrange target 
clones in an overlapping manner. The use of these tiling-arrays can increase resolution 
from ~1Mb to the size of a single clone (~100–200kb), dramatically increasing the 
ability to detect chromosomal deletions and duplications in specific chromosome 
locations.8 It is important to note with this new method, however, that detection is 
most reliable when the abnormality spans more than one clone.8 In theory, therefore, 
resolution is restricted only by the size of an individual target and the density of 
contiguous targets. This leads to the following relationship: the smaller the target 
clone and the higher the density of coverage on the array, the higher the resolution.7 
  Data analysis in acgh
In addition to the aCGH process described, of hybridising two samples of DNA, there 
is also a large data synthesis component in the process that involves sophisticated 
software technology. The applications of this software, as recently reviewed by Chari 
et al. in Computational Methods for the Analysis of Array Comparative Genomic 
Hybridization,9 can be broken down into three primary application stages: data pre-
processing, visualisation, and analysis. Different software packages execute some or 
all of these general functions. 
Data Pre-processing
This stage of the aCGH process occurs after the two genomic samples have 
been mixed and hybridised to the microarray. Preparation for an accurate 
interpretation of the relative dye intensities requires image normalisation and 
the removal of biases potentially interfering with the real biological data. The 
goal is to remove all non-biological sources of variation before interpretation so 
that only the actual chromosomal abnormalities are revealed. 
2
Figure 2 demonstrates how normalised data (right) can provide a cleaner, 
more accurate profile of actual copy number variation in the sample than non-
normalised data (left).9
Figure 2: aCGH and data pre-processing
Source: Chari R., Lockwood W.W. and Lam W.L. Computational methods for the analysis 
of array comparative genomic hybridization. Cancer Informatics 2006 2: 48–58
visualisation
In order to create an accurate visualisation of the processed data, two different 
methods are currently available for visually representing the copy number variation 
detected by the aCGH experiment. These two visualisation techniques are ‘graphical 
representation’ and ‘interactive display’. The first of these, graphical representation, 
is used for lower-density arrays and illustrates the data in an XY graph, by plotting 
the chromosome position (clone order) on the X-axis and the log
2 
signal ratio on 
the Y-axis. Figure 3 is an example of such a graph, showing a PTEN deletion on 
chromosome 10 (indicated by the blue line).9
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Figure 3: Graphical representation of aCGH
Source: Chari R., Lockwood W.W. and Lam W.L. Computational methods for the analysis 
of array comparative genomic hybridization. Cancer Informatics 2006 2: 48–58
The second approach to visualisation, interactive display, is capable of visually 
representing higher-density arrays containing tens of thousands of DNA targets. Each 
chromosome or chromosome segment in the array can be represented individually 
and then magnified for closer analysis. A chromosome ideogram is placed to the left 
of each signal ratio plot. Different software can include additional functions such as 
links to online public databases (OMIM, NCBI Entrez and UCSC Genome Browser) 
and gene track. Figure 4 shows what this visualisation software looks like.9
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Figure 4: Visualisation using interactive display
Source: Chari R., Lockwood W.W. and Lam W.L. Computational methods for the analysis 
of array comparative genomic hybridization. Cancer Informatics 2006 2: 48–58
 
analysis
The most important phase of the aCGH process is the analysis and interpretation 
of data and the detection of chromosome abnormalities in the form of deletions 
and duplications. There are a number of analytical strategies that are frequently 
used for data analysis of genetic alterations (direct thresholding, moving average-
based thresholding, k-means clustering, hidden Markov model, circular binary 
segmentation and wavelet based and genetic local search). By way of illustration, the 
following is a brief explanation of two of these methods.
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1. Direct thresholding: This is the most straightforward analytical method. It 
involves setting a specific threshold pre-defined by the differing signal ratios 
represented by single-copy gains and losses. A single-copy gain theoretically 
appears as a 3:2 ratio, with a log
2
 value of 0.585; while a single-copy loss appears 
as a 1:2 ratio, with a log
2
 value of -1.
2. Moving average-based thresholding: In contrast to direct thresholding, this 
analytic approach implements an average ratio calculated for a specific distance 
with a sliding window. The larger the window (i.e. the more data points 
calculated into the average ratio) the smoother the curve, but the less sensitive 
the detection of alterations. In order to achieve higher sensitivity, a smaller 
window can be used, but the probability of false positives increases. 
Inherent in the process of data analysis is the risk of detecting false positives as well 
as false negatives.9 In order to correct for this potential error, other methods such as 
FISH and QF-PCR can be applied to validate the evidence of chromosome alteration, 
as shown in Figure 5. 
Figure 5: Data pre-processing visualisation analysis
Source: Chari R., Lockwood W.W. and Lam W.L. Computational methods for the analysis 
of array comparative genomic hybridization. Cancer Informatics 2006 2: 48–58
As the use of aCGH transitions from the research setting to the clinical setting, software 
will continue to be developed to meet these needs. Important considerations for the 
future development of this software include increased accessibility for researchers with 
less computational experience, increased automation, security of information and 
integration of previous knowledge of genetic disorders to help interpret analysed data.9 
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  aDvantages anD limitations oF acgh
A promising prenatal diagnostic technique is offered in the form of aCGH, as it 
addresses many of the limitations of previous diagnostic methods such as microscopic 
karyotype analysis, FISH and QF-PCR. The advantages of aCGH can be broken down 
into four general categories: higher-resolution capability; comprehensive screening; 
faster turn-around time; and potential for automation. 
Higher-resolution capability
The ability to detect chromosome abnormalities at a higher resolution using 
aCGH substantially increases the ability to diagnose potential genetic disorders. 
Microscopic karyotyping allows reliable resolution at >10Mb, and has been used 
to detect alterations as small as 3–5Mb, although this is not done routinely.3 FISH 
probes can theoretically achieve resolution as small as the individual probes used 
in the procedure, ~35–200kb, but the process is limited by number and specificity 
of probes.6 The process of aCGH has demonstrated high-resolution detection of 
copy number variation (both deletions and duplications) as small as 100–200kb.8 
This technique has been successful not only in detecting all aneuploidies, but 
also in detecting over forty chromosome alterations and forty-one subtelomeric 
rearrangements.8 The technology is also continually developing and the potential 
for an even higher resolution with oligonucleotide targets may be of clinical value 
in the future.8 
Comprehensive screening
One major limitation in the use of FISH in prenatal diagnosis is that screens 
are substantially limited by the number of probes that researchers can utilise 
simultaneously.7 In addition, researchers must suspect a specific region in order to 
determine which FISH probes to utilise in a given experiment.7 Researchers do not 
always have this knowledge prior to testing. Although this technique can detect the 
common chromosome abnormalities associated with many genetic disorders, it is 
limited in its comprehensive nature, for it can only reliably detect microdeletions 
and could potentially miss chromosome duplications.7 Similarly, QF-PCR cannot 
perform genome-wide screens and, therefore, can potentially fail to spot ~1–2 per 
cent of copy number imbalances.4 The aCGH technology, however, now provides 
a technique through which the entire human genome can be screened in one trial.7 
Different research has utilised different array techniques in order to accomplish 
this. For example, some research has utilised arrays with uniform coverage, such 
as one clone/1Mb, for the entire genome.3,7 Other research has demonstrated a full-
genome screen with contiguous coverage.7 This genome-wide screening capability 
at very high resolution has been of tremendous value to researchers, and has 
played an integral role in the discovery of genes and the detection of chromosome 
deletions and duplications throughout the human genome. 
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Faster turn-around time
In contrast to microscopic karyotyping and conventional CGH, aCGH, in 
addition to FISH and QF-PCR, can be performed on uncultured samples.3 This 
is a significant advantage for the use of this technology in the clinical setting 
because reporting time can be significantly decreased.3 In addition, recent 
research demonstrates that successful aCGH analysis of prenatal material can be 
performed on as little as 1ml of uncultured material.3
Potential for automation
Moreover, aCGH is amenable to automation, making it a highly valuable research 
and clinical diagnostic tool. This characteristic feature of aCGH technology will 
decrease the labour and expense involved as well as decreasing the reporting time 
for results.3 
As well as these advantages, however, there are also limitations to aCGH technology. 
One important consideration is that the genomic alterations aCGH can detect are 
limited in number. Because of the very nature of the aCGH methodology, the process 
will not detect balanced chromosomal rearrangements such as reciprocal and 
Robertsonian translocations and inversions.3,4,7,8 In addition, aCGH does not reliably 
detect polyploidy and low-level mosaicism below 30 per cent.3,4,8 Because detection 
is dictated in part by the size of BAC clones, chromosome alterations that are smaller 
than individual targets may also not be revealed in the analysis.7 There are also 
limitations that are unique to different types of arrays: targeted, and whole-genome, 
arrays. The primary limitation of targeted arrays is that chromosome alterations that 
exist outside the particular scope of the microarray will not be detected. For whole-
genome arrays, a number of limitations with the current technology make it unlikely 
such arrays will soon be widely used for clinical diagnosis. In the light of recent 
research, demonstrating the high copy-number variation in the normal human 
genome,10,11 it is increasingly difficult to interpret data from genome-wide arrays 
that detect copy-number alterations. Whether such variation should be considered 
benign or the cause of disease introduces an additional complexity to the analysis of 
aCGH data.2,7 Also, whole-genome arrays utilise more probes which can lead to an 
increased number of false positives, additional expense and complicated issues with 
regard to quality control.3
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 aDvantages limitations
 acgh – can detect copy-number cannot detect: 
  variation at multiple loci  – low-level mosaicism 
  simultaneously  30 per cent
 – faster turn-around time – balanced chromosomal 
 – can detect deletions,   rearrangements
  duplications and  (reciprocal and  
  amplifications at locus  translocations and
 – potential for automation  inversions) 
 – comprehensive – point mutations7
 – lower cost and labour and  may not be detected: 
  report times – triploidy or polyploidy
 – can detect more complex – abnormalities smaller  
  chromosomal defects   than the size of the
  (double trisomies)8  specific bac target
  targeted array – reliably detects more than – regions not represented 
  forty chromosomal defects,  by chromosome target
  forty-one subtelomeric  will not be analysed 
  rearrangements and all 
  aneuploidy in one 
  diagnostic assay 
 – proved clinical use in cases 
  of mental retardation and 
  learning disability and known 
  chromosome alterations with 
  targeted array   
whole-genome array – ability to perform whole- – difficult to interpret data  
   genome screens at  given new research on   
   unprecedented resolution  the normal human copy-  
     number variation in the   
     genome 
   – requires skilled   
    interpretation
   – lower resolution
    compared to targeted-  
    array cGH
   – not as good for clinical   
    use: more array probes   
    means a higher number   
    of false positives; and   
    more expensive to   
    fabricate, control quality   
    and interrogate 
Table 1: Summary of advantages and limitations of aCGH
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  transition From research to clinical use
Of critical importance is the discussion about how this relatively new technology 
can have an impact on clinical diagnosis and what role it should play in prenatal 
diagnostics. Although aCGH technology has been available since the 1990s, it is only just 
transitioning from research to clinical use. While this represents exciting progress in the 
field of clinical cytogenetics, there are a number of important considerations that must 
be addressed before the technology can be implemented safely and effectively, while 
minimising the potential harms. In the research context, the introduction of aCGH 
technology has led researchers to the discovery of genes and provided a much broader 
picture of the human genome with regard to chromosome structure and function.7 
 The application of aCGH in clinical diagnosis, however, calls for further research and 
developments in available technology. As discussed earlier, the use of whole-genome 
arrays for clinical use is less appropriate at this time given its current limitations. 
These limitations are illustrated by de Vries et al. in their study looking at unexplained 
mental retardation in a sample of one hundred affected individuals.12 Despite the fact 
that all one hundred people demonstrated normal microscopic karyotype results, 
array CGH detected de novo alterations in 10 per cent of the sample (seven deletions 
and three duplications) ranging in size from 540kb to 12Mb. In 97 per cent of the 
patients, however, large-scale copy-number variation was detected; and, upon DNA 
analysis of phenotypically normal parents, it became clear that the majority of these 
alterations were benign rather than disease causing. De novo abnormalities are those 
chromosome alterations that are not inherited from either parent, therefore making 
it more likely that such chromosome imbalances will lead to phenotypic expression. 
This study demonstrates some of the important challenges and limitations of using 
whole-genome arrays in clinical prenatal diagnosis. 
Due to the prevalence of large-scale copy-number variation in the normal human 
genome,10,11,23 interpretation of data can be extremely difficult. Not only is the 
interpretation challenging, it also requires significant resources (labour, funding 
and time) to test parents in order to determine whether a detected chromosome 
variation is clinically significant. This places a financial and technical burden on 
laboratories and can also cause parents and families significant stress and anxiety.7 
In contrast to the use of whole-genome arrays, researchers have constructed targeted 
arrays to examine specific chromosomal regions of known significance, which seem 
more suitable for use in clinical prenatal diagnosis. The use of targeted arrays in 
the clinical setting is still extremely limited, although there is continued progress. A 
review follows of four significant studies specifically designed to evaluate the use of 
targeted aCGH technology for clinical use.
0
Bejjani et al. use of targeted array-based cgh for the clinical diagnosis of 
chromosomal imbalance: is less more? (200)
In this study, the researchers designed a targeted microarray constructed 
specifically to evaluate chromosomal regions of known medical significance. After 
FISH verification of BAC clones for the array, 589 (65 per cent) of the original 
906 BAC clones were used to test fifty control subjects with normal phenotypes 
and thirty-six subjects with known chromosome alterations. In the control cohort, 
aCGH detected deletions and duplications previously undetected by FISH (2p 
pericentromere, 5q telomere, 6p telomere, 7q pericentromere, 14q pericentromere 
and 14q telomere). In addition, the array detected all chromosome single-copy 
abnormalities in the test group. All detections by aCGH were later confirmed by 
FISH. From the results of this work, the authors concluded that: 
Our data demonstrate that the rigorous assessment of BACs and 
their use in array CGH is especially important when the microarray 
is used for clinical diagnosis. In addition, this study illustrates that, 
when constructed carefully with proper attention to the quality of the 
BACs that are arrayed, array CGH is an effective and efficient tool for 
delineating chromosomal aberrations and an important adjunct to FISH 
and conventional cytogenetics.6
rickman et al. Prenatal detection of unbalanced chromosomal rearrangements by 
array cgh (200)
In this study, researchers looked at thirty samples of cultured foetal material with 
two arrays: a specific targeted array, and an array with overall 1Mb resolution. 
The targeted array was designed with ~600 BAC clones evaluating chromosome 
regions of particular interest for aneuploidy, previously known microdeletion 
syndromes and large structural rearrangements. All thirty samples had been 
tested microscopically and were known to have chromosome abnormalities. With 
the custom design array, 29/30 unbalanced chromosome rearrangements were 
detected, whereas the 1Mb array detected only 22/30. The one failed detection 
with the use of the custom array was a case of triploidy. For the 1MB array, 
the test failed to detect chromosome abnormalities in regions that were not 
represented by clones on the array (microdeletions at 4p, 7q11 and 22q11). In 
addition to the study of cultured samples, this study also established the value of 
the custom design array on thirty uncultured samples, delivering the same 29/30 
detections on as little as 1ml of amniotic fluid. The failed detection in this part of 
the experiment was again triploidy. The authors of this work concluded that:
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We believe these results provide proof of principle that array CGH using 
a custom designed array is rapid, and may have about the same overall 
capacity to detect clinically relevant chromosome abnormalities as 
conventional cytogenetics. It has the potential to replace karyotyping for 
prenatal cytogenetics, but considerable further work is required to reach 
consensus on the optimum configuration of an array for clinical use, and 
large trials are needed to demonstrate sensitivity and specificity in clinical 
operating conditions, before the clinical implementation of array CGH 
can be considered.3
schaeffer et al. comparative genomic hybridization-array analysis enhances 
the detection of aneuploidies and submicroscopic imbalances in spontaneous 
miscarriages (200)1
The goal of this study was to determine whether a targeted microarray could 
detect all of the known chromosome abnormalities previously determined by 
G-banding in forty-one ‘products of conception’. It was also of interest whether 
the aCGH array would detect any additional abnormalities that the microscopic 
karyotyping did not detect. In fact, not only did the array detect all established 
chromosome abnormalities, it also discovered previously undetected aberrations 
in four of the forty-one cases (9.8 per cent). A lower-density targeted array was 
utilised in this study, as opposed to a higher-density and higher-resolution array, 
so as to limit the chromosome analysis to clinically relevant regions and clones. 
Because chromosome abnormalities cause the majority of miscarriages, and 
miscarriages occur in as many as 15 per cent of all clinically recognised pregnancies, 
aCGH has the potential to provide a more comprehensive understanding of the 
causes of such tragedies and offer more complete diagnoses in the clinical setting. 
The tremendous value of aCGH technology, therefore, reinforces its potential to 
make significant impact on clinical prenatal diagnosis. This article looks to future 
considerations and progress for aCGH:
Future studies can test the benefits of the array technique in regard to 
higher detection parameters, more accurate and less failure-prone 
diagnoses, and a greater ease of use, as compared with conventional 
cytogenetic analysis.13
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shaffer et al. targeted genomic microarray analysis for identification of 
chromosome abnormalities in 100 consecutive clinical cases (200)1
In this unique and important study, researchers did not explicitly collect 
subjects with particular known chromosome abnormalities; but, rather, studied 
1500 consecutive cases referred to the laboratory for array analysis.7 The idea 
behind this methodology was that these 1500 cases would provide a relatively 
representative cohort of real clinical cytogenetic cases. Of the 1500 patients, array 
analysis revealed that ~9 per cent of cases presented chromosome abnormalities: 
thirty-six patients (2.4 per cent) demonstrated polymorphisms or familial 
variants; fourteen patients (0.9 per cent) demonstrated abnormalities for which 
there was unknown clinical significance; and eighty-four patients (5.6 per cent) 
showed clinically relevant abnormalities. The detected abnormalities, specifically, 
included unbalanced rearrangements, subtelomeric deletions, microdeletions 
and reciprocal duplications as well as rare abnormalities and low-level trisomy 
mosaicism.7,14 The custom design array included 832 BACs, which were 
representative of only 140 loci. The authors of this study concluded that:
Our results showed that microarray analysis likely doubles the yield of 
chromosome abnormalities that is currently detected by conventional 
cytogenetic analysis. … Therefore, in a clinical setting, a significant 
percentage of clinically relevant chromosomal abnormalities can be 
detected by judicious coverage of the genome.7
These studies, as well as others, have quantitatively demonstrated that targeted 
aCGH has significant potential in the field of clinical cytogenetics. Clinicians using 
this screening method in prenatal diagnosis must recognise the limitations of the 
current aCGH technology and take special precaution to limit potential harms. This 
is essential in aCGH’s clinical diagnostic utility. Many of these studies make a number 
of recommendations of important and relevant considerations for the application of 
this technology in a clinical setting.7 They can be summarised as follows:
1. Independent FISH verification: Because BAC clones used in the construction 
of BAC arrays are collected from a variety of sources, such as academic or 
commercial databases,7 there is no absolute guarantee that these BAC clones will 
map to the right genomic location, and not map to more than one location. In 
order to ensure the identity and reliability of individual BACs, individual clones 
should be verified by FISH before use in a clinical array.7,8 
2. Loci represented by more than one BAC clone: By using multiple clones for 
specific loci, the statistical confidence in the results of the analysis increases. If 
only one clone is used, variation could be the result of systematic error rather 
than actual copy-number variation and chromosome abnormality.7
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3. Identification of polymorphic clones: As demonstrated in the research,10,11 
there is large-scale variation in the normal human genome, which means 
that some BAC clones will also express this polymorphic quality, potentially 
complicating clinical diagnosis. It is essential that these polymorphic clones 
are identified, at which point they can be removed from the targeted array or 
remain on the array with particular recognition of their status.7
4. aCGH plus karyotype: Because current targeted arrays do not provide complete 
coverage of each chromosome, it is recommended that karyotype analysis 
be performed in addition to aCGH as a cautionary measure. In addition, if a 
chromosome abnormality is detected by aCGH, the finding should be subjected 
to external confirmation by karyotype analysis or FISH.8
In addition to these technical considerations, there are also questions with regard to 
accessibility and availability of this technology. Two primary questions arise here:8
1. Should aCGH technology be offered to women in addition to invasive 
amniocentesis (AC) and chorionic villus sampling (CVS)? Relevant concerns 
here include expense and increased stress and anxiety for parents and families, 
as well as the possibility of revealing non-paternity in evaluating relatives to 
determine benign or disease-causing chromosome abnormalities.8
2. Should aCGH technology, which currently requires invasive testing of AC 
or CVS, be offered to all pregnant women regardless of risk? Answering this 
question requires an assessment of the relative risks of both AC and CVS in 
relation to the risk of detecting a chromosome abnormality that would not be 
detected with normal Down syndrome screening protocols.8 
Although there is significant potential for the clinical use of aCGH, there are many 
considerations to be addressed when discussing its successful transition from use as 
a research tool to use in clinical prenatal diagnosis.
  guiDelines anD stanDarDs
Because aCGH is still in its very early stages, there are no mandatory guidelines or 
protocols with reference to its specific use in the United States; and there are no 
Federal or State laws that directly apply to the technology. Despite this, a growing 
body of aCGH research is indirectly developing standards for the acceptable uses of 
the current technology, both in research and in the future prospects for its clinical 
application. This research has outlined many of the benefits as well as the limitations 
and potential risks of the aCGH method, a number of which were discussed 
earlier. As this technology continues to develop, and transitions into an applied 
clinical tool, there will be an increasing need for policy decisions and guidelines to 
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direct researchers, clinicians and physicians toward the appropriate use of aCGH. 
Professional organisations, such as the American College of Medical Genetics 
(ACMG), the American College of Obstetricians and Gynecologists (ACOG), the 
American Academy of Pediatrics (AAP) and others, will play a significant role in 
influencing the direction of aCGH use in the research and clinical contexts. Although 
the recommendations of these professional organisations are not legally binding, 
and membership is voluntary, guidelines and recommendations published by these 
bodies carry significant weight in the medical community. 
American College of Medical Genetics (ACMG)
Although the ACMG has not taken an explicit position on aCGH, the ACMG 
Laboratory Quality Assurance (QA) Committee publishes Standards and 
Guidelines for Clinical Genetics Laboratories (2006).15 The ACMG reports the 
purpose of these standards as follows:
These voluntary standards have been established as an educational 
resource to assist medical geneticists in providing accurate and reliable 
diagnostic genetic laboratory testing consistent with currently available 
technology and procedures in the areas of clinical cytogenetics, biochemical 
genetics and molecular diagnostics.15 
These standards fall into the categories of personnel policies, general policies, 
shared methodologies, clinical cytogenetics, clinical biochemical genetics and 
clinical molecular genetics, as well as standards and guidelines for the genetic 
testing of specific genetic disorders such as Down syndrome, fragile X, Huntington 
disease, open neural tube defects and ultra rare disorders.15 Although aCGH is 
not mentioned in these sections, there are regulations and standards outlined 
for similar diagnostic tools such as FISH and PCR. Specifically, ACMG is now 
developing technical and clinical practice standards for the use of aCGH. In 
addition, recommendations for acceptable use could also be integrated into 
guidelines for particular disorders for which aCGH technology could be applicable, 
e.g. Technical Standards and Guidelines: Prenatal Screening for Down Syndrome 
(2006).16 These standards cover wide-ranging technical considerations and also 
integrate issues such as information distribution for patients and health-care 
providers and informed consent.
American College of Obstetricians and Gynecologists (ACOG)
Like ACMG, ACOG is a professional organisation that releases guidelines, 
committee opinions and publications on various medical topics relating to 
women’s health care. In relation to standards and guidelines for aCGH technology, 
ACOG has a committee on genetics, which publishes committee opinions on a 
number of genomic related subjects. Although it too has not presented an opinion 
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on aCGH technology and its potential clinical utility, there could be a place for 
relevant guidelines, recommendations or opinions on this subject in the future. 
In the last two years, the committee on genetics has published opinions such 
as First-Trimester Screening for Fetal Aneuploidy (2004)17 and Prenatal and 
Preconceptional Carrier Screening for Genetic Diseases in Individuals of Eastern 
European Jewish Descent (2004).18 ACOG recommends that all pregnant women, 
regardless of age, be offered screening for Down syndrome in the first trimester.24 
ACOG recommends that non-invasive screening techniques such as nuchal 
translucency in conjunction with standard blood tests be offered to women in the 
general population, with AC or CVS as a follow-up test. ACOG also recommends 
that AC or CVS be offered to women known by other means to be of high risk 
for foetuses with Down syndrome (for example, those who have had a child with 
Down syndrome). This recommendation will increase the number of women 
potentially using aCGH.
American Academy of Pediatrics (AAP)
The AAP Policy is a collection of policy statements, clinical reports, clinical 
practice guidelines and technical reports by the AAP. Although this organisation 
also has not published explicit opinions on the use of aCGH in the clinical setting, 
or even in a research context, it did publish a clinical report in 2004 entitled 
Prenatal Screening and Diagnosis for Pediatricians (2004).19 This document 
offers physicians and clinicians guidance in the appropriate handling of situations 
with regard to potential genetic abnormalities. The purpose of this report is:
To update the pediatrician about indications for prenatal diagnosis, 
current techniques used for prenatal diagnosis, and the status of maternal 
screenings for detection of fetal abnormalities.19
Although aCGH technology is not yet widely used for prenatal diagnosis in the 
clinical setting, it is this type of clinical report that could help to construct the 
necessary guidelines and professional recommendations. 
Many researchers have integrated standards and opinions about the use of aCGH 
into their publications, in place of actual guidelines. Publications cover such topics 
as the circumstances in which it is appropriate to utilise aCGH technology; whether 
genome-wide arrays or targeted arrays should be used; and what precautions should 
be taken in the clinical application of aCGH technology. Researchers are evaluating 
not only the technical side of the new diagnostic method, but also, more broadly, 
the clinical impact this technique could have on medicine in general and on patients 
and families. As the clinical use of this technique becomes a reality in prenatal 
diagnostics, more comprehensive guidance for researchers, clinicians and physicians 
will be necessary.
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7  ethical, legal anD social imPlications
Before aCGH can be introduced for clinical prenatal diagnosis, a comprehensive 
analysis is necessary of the new technology’s ethical, legal and social implications. 
Although aCGH holds significant medical promise, there are a number of complex 
and controversial issues that must be addressed. These questions are not necessarily 
unique to aCGH but rather apply to the rapidly developing field of genetics in 
general. Projects such as ACCE, a Centers for Disease Control and Prevention (CDC)-
sponsored project, and the Human Genome Project’s Ethical, Legal and Social Issues 
(ELSI) research, are examples of different frameworks by which to evaluate new 
genetic technology in terms of the broader implications of clinical use.
National Office of Public Health Genomics: ACCE project
This CDC-funded project has created a comprehensive model, as shown in Figure 
6, to evaluate genetic tests and data according to four specific principles (from 
which it takes its name): analytic validity; clinical validity; clinical utility; and 
ethical, legal and social implications.20 The model offers an abstract guideline 
for this assessment and can be of tremendous value in determining whether a 
particular genetic technology, in this case aCGH, is ready for clinical application. 
Figure 6: The ACCE evaluation process for genetic testing
Source: National Office of Public Health Genomics website: http://www.cdc.gov/
genomics/gtesting/ACCE.htm
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Human Genome Project: ELSI research 
This programme represents a small component of the larger Human Genome 
Project, providing a comprehensive outline of ethical, legal and social issues with 
regard to genetic testing and new genetic technology.21 The goal of this research 
is to examine relevant issues and offer preliminary recommendations and 
considerations in order to promote the potential benefits of this technology while 
also minimising potential risks. These broad societal implications and concerns 
are broken down into a number of categories,21 including but not limited to:
 1.  Privacy and confidentiality of genetic information
  – Who owns and controls genetic information?
 2.  Psychological impact and stigmatisation
  – How does personal genetic information affect an individual and  
   society’s perceptions of that individual?
  – How does genomic information affect members of minority   
   communities?
 3.  Reproductive issues
  – Adequate informed consent for complex and controversial procedures;  
   use of genetic information in reproductive decision-making; and  
   reproductive rights
 4.  Clinical issues
  – Education of physicians, patients and the general public in   
   genetic capabilities, scientific limitations and social risks; and   
   implementation of standards and quality-control measures in testing  
   procedures
 5.  Uncertainty
  – Should testing be performed when no treatment is available?
  – Are genetic tests reliable and able to be interpreted by the medical 
   community?21
These general models offer a starting point from which to examine the benefits 
and possible risks in genetics. However there are also a number of specific ethical 
and social issues that must be discussed in the light of the specific application and 
use of aCGH. The following is an analysis of various issues to be considered when 
examining the value and potential harms of clinical use of aCGH.
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Justification of prenatal diagnosis
The first step in analysing the implications of aCGH technology is to understand 
why such a tool is useful and representative of advances in medicine. The prenatal 
screening capability of this method will provide physicians and parents with 
additional information about a pregnancy that could potentially affect a number 
of pregnancy-related issues:
Pregnancy termination: Because aCGH can detect chromosome 
abnormalities of known clinical significance leading to many severe 
disorders, parents may choose to terminate a pregnancy once they know 
that the foetus is affected. 
Preparation for child: In learning that a foetus is affected by a 
chromosome alteration that causes severe genetic disorders, parents will 
have the ability to properly prepare for the birth of an affected child. This 
could mean becoming educated on the disorder itself, researching options 
related to childcare and undertaking financial planning. 
Pregnancy management: Often knowledge of a chromosome abnormality 
can contribute to a physician’s efficacy and success with regard to 
management of the pregnancy as well as the delivery. 
PGD: If aCGH technology progresses to the point where it can be used to 
clinically screen embryos for disease-causing genetic alterations, it could 
play an integral role in PGD. This potentially offers families who would 
otherwise choose not to become pregnant due to familial genetic disorders 
the option of having a healthy child. 
Alongside these justifications for prenatal diagnosis, there are additional ethical 
considerations with regard to pregnancy termination and PGD.
Acceptable or appropriate use of aCGH
As aCGH technology becomes available for clinical use, there will be a number 
of questions raised as to the acceptability of its use in prenatal diagnosis. In the 
current research and development phase, the technology is being used to identify 
genetic alterations that lead to serious conditions such as Down syndrome, and 
potentially fatal disorders such as Patau syndrome. However, there is potential 
for this technology to detect less severe genetic disorders; this raises serious 
concerns when parents may consider termination of pregnancy due to positive 
test results.22 How severe is severe enough to justify ending a pregnancy in view of 
prenatal diagnostic results? As it becomes possible to screen for more minor genetic 
alterations, leading to less severe conditions, it may be necessary to evaluate for 
which disorders and genetic alterations it is appropriate to screen. The large 
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number of variants identified by aCGH, the clinical significance of which is 
unclear, will make decision-making more difficult for parents. Furthermore, the 
faster turn-around time of aCGH makes it more attractive for use in PGD, but 
will put increased pressure on prospective parents to make reproductive decisions 
in a short timeframe based on large amounts of imprecise information.
Test uncertainty
With aCGH, as with any diagnostic test, there is a certain risk of false positive 
results. At this stage of development of aCGH, there will be many results 
of uncertain clinical significance.3 If the test were used to confirm a clinical 
diagnosis based on other clinical observations, the results of aCGH would be 
more interpretable than if the test were used as a prenatal diagnostic test. These 
tests introduce complicated issues for parents with regard to decision-making 
in the absence of correct or complete test results. A false positive, for example, 
may lead parents to terminate the pregnancy. In addition, it is not always the 
case that a particular abnormal genotype will lead to a particular phenotype. 
The inability to confirm that such a genomic alteration will lead to a specific 
phenotype could also lead to difficult decisions for the parents. In either case, these 
tests can also unnecessarily increase stress and anxiety for patients and families. 
Extreme caution and sensitivity is necessary both in the technical application of 
this technology (leading to fewer false positives, etc.), but also in the test result 
reporting phase, which requires the involvement of families.14
Privacy
When used as an alternative to traditional karyotyping, aCGH includes analysis 
across the entire genome to detect abnormalities in chromosomal integrity. Thus, 
in contrast to a more targeted examination, such as looking for specific point 
mutations in genes known to be associated with diseases such as cystic fibrosis 
or breast cancer, aCGH has the potential to yield unanticipated or unwanted 
information. Furthermore, it may yield information about family members. This 
is not unique to aCGH analysis, but the breadth and specificity of the analysis 
may give rise to much more, and more specific, unexpected information than 
traditional karyotyping. If used in the prenatal or PGD setting, parental samples 
are sometimes also analysed to aid in interpretation of the proband. In these 
cases, clinicians may face the situation of having to decide whether to disclose to 
the adults clinically significant information that arises in the context of testing 
their embryo or foetus.
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Access to aCGH
As discussed, there are a number of questions that must be answered regarding 
to whom this technology will be offered and whether it should be available to all 
pregnant women, regardless of risk factors such as maternal age and previous 
familial genetic disorders.8, 22 These questions will become more important as 
aCGH is increasingly used for clinical prenatal diagnosis outside of the research 
context. Because current aCGH technology uses samples from invasive testing 
(AC and CVS), a risk assessment will be necessary to determine whether aCGH 
is a potential option. Another component of this will be a financial assessment 
of the clinical use of aCGH, including laboratory costs and insurance coverage 
issues. The question of access to this technology is an important social and ethical 
consideration in the transition of aCGH from research to clinical use. 
Education and counselling
For appropriate use of aCGH, genetic counselling will be needed to help families 
understand the process of genetic testing19 and make informed decisions, especially 
in the context of prenatal testing. Understanding and interpreting the results of 
aCGH, in the context of genetic disorders and genetic tests, will be challenging 
for clinicians, patients and families. The many uncertainties about the clinical 
validity and utility of variation in DNA copy number, and the large amount of 
information generated by whole genome analysis, will make aCGH especially 
challenging for educators and counsellors. Parents and families facing decisions 
with regard to these issues must be fully informed on appropriate tests and 
the implications of positive results. However, the sheer volume of information 
about hundreds or thousands of loci in the genome will be difficult to process by 
counsellors and families. 
 
  recommenDations
At this stage of the development of aCGH technology, a number of recommendations 
can be made for clinical use. These recommendations should be revisited as 
information about its clinical validity and utility is obtained, and as the accuracy, 
resolution and cost of aCGH-based tests evolve.
First, aCGH should be used for prenatal testing only under research protocols where 
other data necessary for learning how to interpret aCGH data are also collected. This 
information might include results of other prenatal screening tests (such as nuchal 
translucency and multiple marker blood tests) and clinical data on parents. The 
aCGH data should be validated by and compared to some other method such as 
standard karyotyping, FISH and QF-PCR.
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Secondly, before clinical use as a prenatal test, aCGH should be used and evaluated 
under conditions that allow assessment of the clinical significance of the results 
(i.e., where phenotype and clinical information about the patient is available, from 
newborns, children or adults). Given the large amount of copy-number variation 
in the general population, even among apparently healthy people, the finding of 
copy-number variants may in itself be of unclear clinical significance. In the prenatal 
setting, very little clinical information can be obtained to aid in the interpretation 
of aCGH results, and it is thus not the optimal setting in which first to bring the 
technology to clinical use.
Thirdly, laboratories beginning to use aCGH should adopt uniform and transparent 
technical standards, including standards for what constitute the ‘normal’ control 
samples with which patient samples are compared.
Fourthly, research and clinical laboratories using aCGH should anticipate the 
possibility of uncovering ‘incidental’ findings and make plans for handling them. 
For example, if parental samples are tested, in order to interpret the findings from a 
foetal sample tested to detect trisomy 21, the laboratory should make advance plans 
for whether and how to report unexpected findings of major clinical significance that 
arise in the parental samples. Laboratories should also decide whether any results will 
be withheld.
Fifthly, informed consent to aCGH in research or clinical settings should include 
provisions for how research subjects or patients want to handle ‘incidental’ findings, 
the possibility of unwanted results and results of unknown clinical significance.
9  conclusion
The diagnostic power of aCGH technology offers an exciting and revolutionary 
approach to prenatal diagnosis, providing a much more fine-grained tool for genetic 
analysis than other currently available technologies. The detection capability, as a 
result of increased resolution, the comprehensive nature of the tests and the potential 
for faster reporting times, all make aCGH a promising new technique. However, 
despite the documented successes of this technology so far, more research is needed 
to understand its full scope so that aCGH can be implemented as a clinical tool in 
prenatal diagnosis. Because the technique has not yet transitioned to clinical use, there 
are as yet no established standards for its application. To be sure, ethical difficulties 
and ambiguities will attend its clinical use. Research will no doubt continue to 
improve the technology, but it is also important that the ethical, legal and social 
implications enter the discussion as aCGH transitions to clinical use. 
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